If I am not mistaken that’s to be considered at and counting but this explains more: www.jnj.com/media-center...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
• Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson’s RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease • Consistent responses observed across aty...
www.jnj.com
May 31, 2026 at 7:49 PM
If I am not mistaken that’s to be considered at and counting but this explains more: www.jnj.com/media-center...
Aetna is refusing to pay for my Lazcluze immunotherapy treatment. I have been on the medicine for a year. They want me to try another medicine even though this one is working, and two others I've already tried had serious adverse effects. Trying another medicine could seriously disable me or worse.
October 10, 2025 at 11:04 PM
Aetna is refusing to pay for my Lazcluze immunotherapy treatment. I have been on the medicine for a year. They want me to try another medicine even though this one is working, and two others I've already tried had serious adverse effects. Trying another medicine could seriously disable me or worse.
Press release: MARIPOSA regimen of first-line amivantamab plus lazertinib shows a significant improvement in overall survival over osimertinib alone in #EGFR NSCLC. Full data to be presented but improvement in median OS expected to be over 12 months.
www.jnj.com/media-center...
www.jnj.com/media-center...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib
Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer
www.jnj.com
January 7, 2025 at 1:34 PM
Press release: MARIPOSA regimen of first-line amivantamab plus lazertinib shows a significant improvement in overall survival over osimertinib alone in #EGFR NSCLC. Full data to be presented but improvement in median OS expected to be over 12 months.
www.jnj.com/media-center...
www.jnj.com/media-center...
Johnson & Johnson reported that their #EGFR non-small cell lung cancer drug combo of Rybrevant & Lazcluze in Phase 3 clinical trial had impressive overall survival (OS) data over standard-of-care & improved survival by at least a year statnews.com/2025/01/07/l... #NSCLC
January 7, 2025 at 6:51 PM
Johnson & Johnson reported that their #EGFR non-small cell lung cancer drug combo of Rybrevant & Lazcluze in Phase 3 clinical trial had impressive overall survival (OS) data over standard-of-care & improved survival by at least a year statnews.com/2025/01/07/l... #NSCLC
🆙MARIPOSA🦋OS positive
🎯Amivantamab-vmjw plus lazertinib shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib
#LCSM @oncoalert.bsky.social #EGFR
www.jnj.com/media-center...
🎯Amivantamab-vmjw plus lazertinib shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib
#LCSM @oncoalert.bsky.social #EGFR
www.jnj.com/media-center...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib
Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer
www.jnj.com
January 7, 2025 at 1:30 PM
🆙MARIPOSA🦋OS positive
🎯Amivantamab-vmjw plus lazertinib shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib
#LCSM @oncoalert.bsky.social #EGFR
www.jnj.com/media-center...
🎯Amivantamab-vmjw plus lazertinib shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib
#LCSM @oncoalert.bsky.social #EGFR
www.jnj.com/media-center...
The Johnson and Johnson Phase III MARIPOSA trial of the activity of Rybrevant and Lazcluze as anti-EGFR therapy for NSCLC demonstrated significant improvement of progression-free survival compared to Tagrisso.
www.genomeweb.com/cancer/liqui...
www.genomeweb.com/cancer/liqui...
Liquid Biopsy Elucidates Resistance Mechanisms With Targeted Treatment Combo in EGFR-Mutated NSCLC
Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.
www.genomeweb.com
September 26, 2024 at 3:47 PM
The Johnson and Johnson Phase III MARIPOSA trial of the activity of Rybrevant and Lazcluze as anti-EGFR therapy for NSCLC demonstrated significant improvement of progression-free survival compared to Tagrisso.
www.genomeweb.com/cancer/liqui...
www.genomeweb.com/cancer/liqui...
La FDA a approuvé le Rybrevant associé au Lazcluze pour le #traitement de première ligne des adultes atteints d'un #cancer du poumon.
www.boursorama.com/bourse/actua...
www.boursorama.com/bourse/actua...
Johnson & Johnson: approbation en cancer du poumon
(CercleFinance.com) - Johnson & Johnson annonce que la FDA des Etats-Unis a approuvé Rybrevant associé à Lazcluze pour le traitement de première ligne des adultes atteints d'un cancer du poumon non à ...
www.boursorama.com
August 20, 2024 at 1:35 PM
La FDA a approuvé le Rybrevant associé au Lazcluze pour le #traitement de première ligne des adultes atteints d'un #cancer du poumon.
www.boursorama.com/bourse/actua...
www.boursorama.com/bourse/actua...
Each year I invariably look up the FDA Novel Drug Approval list to have a laugh at the names, and I hoped this year’s list would help cut some gloom… but 2025 is pretty weak, especially compared to 2024 when we had Crenessity, Unloxcyt, Flyrcado *and* Lazcluze. And who can forget 2023’s Beyfortus.
September 4, 2025 at 3:20 AM
Each year I invariably look up the FDA Novel Drug Approval list to have a laugh at the names, and I hoped this year’s list would help cut some gloom… but 2025 is pretty weak, especially compared to 2024 when we had Crenessity, Unloxcyt, Flyrcado *and* Lazcluze. And who can forget 2023’s Beyfortus.
My heart is improving. I still have a way to go, but my recovery offers more proof that it was Tagrisso and not other factors that led to the issue. So far, so good on Lazcluze.
I got the OK to take short trips again. Bout to catch me some flights rather than feelings.
#FridayFeeeling
I got the OK to take short trips again. Bout to catch me some flights rather than feelings.
#FridayFeeeling
October 25, 2024 at 10:50 PM
My heart is improving. I still have a way to go, but my recovery offers more proof that it was Tagrisso and not other factors that led to the issue. So far, so good on Lazcluze.
I got the OK to take short trips again. Bout to catch me some flights rather than feelings.
#FridayFeeeling
I got the OK to take short trips again. Bout to catch me some flights rather than feelings.
#FridayFeeeling
NEWS: #JohnsonandJohnson has been saying for some time that it thinks its combination of Rybrevant and Lazcluze is the best option for patients with #EGFR mutated non-small cell #lungcancer (NSCLC) – and now it has even stronger survival data to back up its claim.
pharmaphorum.com/news/jj-thro...
pharmaphorum.com/news/jj-thro...
March 27, 2025 at 10:41 AM
NEWS: #JohnsonandJohnson has been saying for some time that it thinks its combination of Rybrevant and Lazcluze is the best option for patients with #EGFR mutated non-small cell #lungcancer (NSCLC) – and now it has even stronger survival data to back up its claim.
pharmaphorum.com/news/jj-thro...
pharmaphorum.com/news/jj-thro...
… T cell immunotherapy, treats metastatic synovial sarcoma; lazertinib (Lazcluze), a kinase inhibitor, is used with amivantamab for EGFR-mutated NSCLC; seladelpar (Livdelzi), a peroxisome proliferator-activated receptor agonist, treats primary biliary cholangitis.
End
3/3
End
3/3
January 1, 2025 at 2:38 PM
… T cell immunotherapy, treats metastatic synovial sarcoma; lazertinib (Lazcluze), a kinase inhibitor, is used with amivantamab for EGFR-mutated NSCLC; seladelpar (Livdelzi), a peroxisome proliferator-activated receptor agonist, treats primary biliary cholangitis.
End
3/3
End
3/3
Stat News story also said "Rybrevant plus Lazcluze combination therapy has more severe side effects compared to Tagrisso alone, with the interim study showing 75% of patients experiencing severe adverse events on the combo compared to 43% of patients who received Tagrisso.....Rybrevant 2/n #biosky
January 7, 2025 at 6:55 PM
Stat News story also said "Rybrevant plus Lazcluze combination therapy has more severe side effects compared to Tagrisso alone, with the interim study showing 75% of patients experiencing severe adverse events on the combo compared to 43% of patients who received Tagrisso.....Rybrevant 2/n #biosky
Thoughts on this? >> J&J touts new survival data for lung cancer
combo >> Comment below! #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #healthcare #biotech #productmarketing
combo >> Comment below! #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #healthcare #biotech #productmarketing
J&J touts new survival data for lung cancer
combo
Johnson & Johnson released new data suggesting its lung cancer combination Rybrevant and Lazcluze beat AstraZeneca’s Tagrisso on overall survival. In a Phase 3 trial, 56% of patients who took J&J’s combination treatment were alive ...
dlvr.it
March 26, 2025 at 4:29 PM
Thoughts on this? >> J&J touts new survival data for lung cancer
combo >> Comment below! #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #healthcare #biotech #productmarketing
combo >> Comment below! #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #healthcare #biotech #productmarketing
Promising Results for New Lung Cancer Treatment at WCLC 2026 with RYBREVANT FASPRO and LAZCLUZE#South_Korea#Seoul#Johnson_&_Johnson#LAZCLUZE#RYBREVANT_FASPRO
Promising Results for New Lung Cancer Treatment at WCLC 2026 with RYBREVANT FASPRO and LAZCLUZE
At WCLC 2026, Johnson & Johnson revealed that RYBREVANT FASPRO and LAZCLUZE show low treatment-related events in lung cancer patients. Discover the findings.
third-news.com
September 15, 2026 at 3:12 AM
Promising Results for New Lung Cancer Treatment at WCLC 2026 with RYBREVANT FASPRO and LAZCLUZE#South_Korea#Seoul#Johnson_&_Johnson#LAZCLUZE#RYBREVANT_FASPRO
EGFR変異肺がんのアミバンタマブ皮下注製剤、予防的対策併用でCOPERNICUS試験が低い治療関連事象を報告──Johnson & Johnsonが発表
stellanews.life/technology/1... #COPERNICUS #皮下注
stellanews.life/technology/1... #COPERNICUS #皮下注
EGFR変異肺がんのアミバンタマブ皮下注製剤、予防的対策併用でCOPERNICUS試験が低い治療関連事象を報告──Johnson & Johnsonが発表
Johnson & Johnsonは2026年9月14日、皮下注製剤RYBREVANT FASPRO（アミバンタマブ・ヒアルロニダーゼ配合）とLAZCLUZE（レーザチニブ）の併用療法に予防的対策を組み合わせたCOPERNICUS試験の結果をWCLC 2026で発表した。皮疹・血栓症・治療中止率の低さを整理する。
stellanews.life
September 16, 2026 at 10:34 PM
EGFR変異肺がんのアミバンタマブ皮下注製剤、予防的対策併用でCOPERNICUS試験が低い治療関連事象を報告──Johnson & Johnsonが発表
stellanews.life/technology/1... #COPERNICUS #皮下注
stellanews.life/technology/1... #COPERNICUS #皮下注
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
#LungCancer
www.jnj.com/media-center...
#LungCancer
www.jnj.com/media-center...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
• Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson’s RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease • Consistent responses observed across aty...
www.jnj.com
August 24, 2026 at 7:07 PM
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
#LungCancer
www.jnj.com/media-center...
#LungCancer
www.jnj.com/media-center...
Lazertinib available in India: 247qualitymeds.com/product/laze...
Buy Lazertinib Tablets Online in India | 24/7QualityMeds
Buy Lazertinib (Lazcluze) tablets online in India at genuine price. Contact 24/7QualityMeds at +91 9967979080 for pricing, availability & safe delivery.
247qualitymeds.com
August 1, 2026 at 11:03 AM
Lazertinib available in India: 247qualitymeds.com/product/laze...
Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows
https://cancerletter.com/clinical-roundup/20250912_10a/
https://cancerletter.com/clinical-roundup/20250912_10a/
Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows - The Cancer Letter
Rybrevant (amivantamab-vmjw) + Lazcluze (lazertinib) demonstrated a statistically significant and clinically meaningful overall survival improvement for patients with previously untreated locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations, according to data from the phase III Mariposa study. To access this subscriber-only content please […]
cancerletter.com
September 15, 2025 at 3:30 PM
Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows
https://cancerletter.com/clinical-roundup/20250912_10a/
https://cancerletter.com/clinical-roundup/20250912_10a/
Rybrevant + Lazcluze show improvement in OS versus osimertinib. #LungCancer
https://cancerletter.com/clinical-roundup/20250110_9b
https://cancerletter.com/clinical-roundup/20250110_9b
Rybrevant + Lazcluze show improvement in OS versus osimertinib - The Cancer Letter
Johnson & Johnson announced positive topline results for overall survival from the phase III MARIPOSA study, evaluating Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions (ex19del) or L858R substitution mutations. To access this subscriber-only content […]
cancerletter.com
January 14, 2025 at 2:00 PM
Rybrevant + Lazcluze show improvement in OS versus osimertinib. #LungCancer
https://cancerletter.com/clinical-roundup/20250110_9b
https://cancerletter.com/clinical-roundup/20250110_9b
